1
|
Wang Z, Liao S, Chen H, Wu S, Liu Z, Liu Y, Hu T, Sun J, Wang K, Xin L, Cai J, Li Y. Identification, synthesis, and characterization of thermal degradants of brivaracetam. SYNTHETIC COMMUN 2023; 53:1601-1615. [DOI: 10.1080/00397911.2023.2238224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Indexed: 12/07/2023]
Affiliation(s)
- Zhongqing Wang
- School of Pharmacy, Xiangnan University, Chenzhou, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, P. R. China
| | - Shouzhu Liao
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Hongjun Chen
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Shuming Wu
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, P. R. China
| | - Zhuangfeng Liu
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Yuting Liu
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Ting Hu
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Jiaxiang Sun
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Kunteng Wang
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Libo Xin
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Jinghui Cai
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| | - Yanhua Li
- Department of Process Research and Development, HEC Pharm Group, Dongguan, P. R. China
| |
Collapse
|
2
|
ALSaeedy M, Hasan A, Al-Adhreai A, Alrabie A, Qaba H, Mashrah A, Öncü-Kaya EM. An overview of liquid chromatographic methods for analyzing new generation anti-epileptic drugs. J LIQ CHROMATOGR R T 2022. [DOI: 10.1080/10826076.2022.2134146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Mohammed ALSaeedy
- Department of Chemistry, Faculty of Applied Sciences, Dhamar University, Dhamar, Yemen
- Department of Chemistry, Faculty of Sciences, Eskisehir Technical University, Eskisehir, Turkey
- Department of Chemistry, Faculty of Education-Albaydha, Albaydha University, Albaydha, Yemen
| | - Ahmed Hasan
- Department of Pharmacology, Graduation School of Health Science, Anadolu University, Eskisehir, Turkey
| | - Arwa Al-Adhreai
- Department of Chemistry, Faculty of Applied Sciences, Dhamar University, Dhamar, Yemen
- Department of Chemistry, Maulana Azad of Arts, Science and Commerce, Aurangabad, India
| | - Ali Alrabie
- Department of Chemistry, Faculty of Education-Albaydha, Albaydha University, Albaydha, Yemen
- Department of Chemistry, Maulana Azad of Arts, Science and Commerce, Aurangabad, India
| | - Hafsah Qaba
- Department of Analytical Chemistry, Graduation School of Health Sciences, Anadolu University, Eskisehir, Turkey
| | - Abdulrahman Mashrah
- Department of Food Science and Technology, Faculty of Agriculture and Food Sciences, Ibb University, Ibb, Yemen
- Department of Food Engineering, Institute of Natural Sciences-Sakarya, Sakarya University, Sakarya, Turkey
| | - Elif Mine Öncü-Kaya
- Department of Chemistry, Faculty of Sciences, Eskisehir Technical University, Eskisehir, Turkey
| |
Collapse
|
3
|
Da Costa GV, Neto MFA, Da Silva AKP, De Sá EMF, Cancela LCF, Vega JS, Lobato CM, Zuliani JP, Espejo-Román JM, Campos JM, Leite FHA, Santos CBR. Identification of Potential Insect Growth Inhibitor against Aedes aegypti: A Bioinformatics Approach. Int J Mol Sci 2022; 23:8218. [PMID: 35897792 PMCID: PMC9332482 DOI: 10.3390/ijms23158218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 06/30/2022] [Accepted: 07/11/2022] [Indexed: 02/04/2023] Open
Abstract
Aedes aegypti is the main vector that transmits viral diseases such as dengue, hemorrhagic dengue, urban yellow fever, zika, and chikungunya. Worldwide, many cases of dengue have been reported in recent years, showing significant growth. The best way to manage diseases transmitted by Aedes aegypti is to control the vector with insecticides, which have already been shown to be toxic to humans; moreover, insects have developed resistance. Thus, the development of new insecticides is considered an emergency. One way to achieve this goal is to apply computational methods based on ligands and target information. In this study, sixteen compounds with acceptable insecticidal activities, with 100% larvicidal activity at low concentrations (2.0 to 0.001 mg·L−1), were selected from the literature. These compounds were used to build up and validate pharmacophore models. Pharmacophore model 6 (AUC = 0.78; BEDROC = 0.6) was used to filter 4793 compounds from the subset of lead-like compounds from the ZINC database; 4142 compounds (dG < 0 kcal/mol) were then aligned to the active site of the juvenile hormone receptor Aedes aegypti (PDB: 5V13), 2240 compounds (LE < −0.40 kcal/mol) were prioritized for molecular docking from the construction of a chitin deacetylase model of Aedes aegypti by the homology modeling of the Bombyx mori species (PDB: 5ZNT), which aligned 1959 compounds (dG < 0 kcal/mol), and 20 compounds (LE < −0.4 kcal/mol) were predicted for pharmacokinetic and toxicological prediction in silico (Preadmet, SwissADMET, and eMolTox programs). Finally, the theoretical routes of compounds M01, M02, M03, M04, and M05 were proposed. Compounds M01−M05 were selected, showing significant differences in pharmacokinetic and toxicological parameters in relation to positive controls and interaction with catalytic residues among key protein sites reported in the literature. For this reason, the molecules investigated here are dual inhibitors of the enzymes chitin synthase and juvenile hormonal protein from insects and humans, characterizing them as potential insecticides against the Aedes aegypti mosquito.
Collapse
Affiliation(s)
- Glauber V. Da Costa
- Graduate Program in Network in Pharmaceutical Innovation, Federal University of Amapá, Macapá 68902-280, AP, Brazil;
- Laboratory of Modeling and Computational Chemistry, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil;
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Moysés F. A. Neto
- Laboratory Molecular Modeling, State University of Feira de Santana, Feira de Santana 44036-900, BA, Brazil; (M.F.A.N.); (F.H.A.L.)
| | - Alicia K. P. Da Silva
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Ester M. F. De Sá
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Luanne C. F. Cancela
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Jeanina S. Vega
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Cássio M. Lobato
- Laboratory of Modeling and Computational Chemistry, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil;
- Laboratory of Biotechnology in Natural Products, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil; (A.K.P.D.S.); (E.M.F.D.S.); (L.C.F.C.); (J.S.V.)
| | - Juliana P. Zuliani
- Laboratory Cellular Immunology Applied to Health, Oswaldo Cruz Foundation, FIOCRUZ Rondônia, Porto Velho 78912-000, RO, Brazil;
| | - José M. Espejo-Román
- Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy, Institute of Biosanitary Research ibs, University of Granada, 18071 Granada, Spain; (J.M.E.-R.); (J.M.C.)
| | - Joaquín M. Campos
- Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy, Institute of Biosanitary Research ibs, University of Granada, 18071 Granada, Spain; (J.M.E.-R.); (J.M.C.)
| | - Franco H. A. Leite
- Laboratory Molecular Modeling, State University of Feira de Santana, Feira de Santana 44036-900, BA, Brazil; (M.F.A.N.); (F.H.A.L.)
| | - Cleydson B. R. Santos
- Graduate Program in Network in Pharmaceutical Innovation, Federal University of Amapá, Macapá 68902-280, AP, Brazil;
- Laboratory of Modeling and Computational Chemistry, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil;
- Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy, Institute of Biosanitary Research ibs, University of Granada, 18071 Granada, Spain; (J.M.E.-R.); (J.M.C.)
| |
Collapse
|
4
|
Teng Y, Gu C, Chen Z, Jiang H, Xiong Y, Liu D, Xiao D. Advances and applications of chiral resolution in pharmaceutical field. Chirality 2022; 34:1094-1119. [PMID: 35676772 DOI: 10.1002/chir.23453] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 03/07/2022] [Accepted: 04/12/2022] [Indexed: 11/07/2022]
Abstract
The attention to chiral drugs has been raised to an unprecedented level as drug discovery and development strategies grow rapidly. However, separation of enantiomers is still a huge task, which leads to an increasing significance to equip a wider range of expertise in chiral separation science to meet the current and future challenges. In the last few decades, remarkable progress of chiral resolution has been achieved. This review summarizes and classifies chiral resolution methods in analytical scale and preparative scale systematically and comprehensively, including crystallization-based method, inclusion complexation, chromatographic separation, capillary electrophoresis, kinetic resolution, liquid-liquid extraction, membrane-based separation, and especially one bold new progress based on chiral-induced spin selectivity theory. The advances and recent applications will be presented in detail, in which the contents may bring more thinking to wide-ranging readers in various professional fields, from analytical chemistry, pharmaceutical chemistry, natural medicinal chemistry, to manufacturing of drug production.
Collapse
Affiliation(s)
- Yan Teng
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
| | - Chenglu Gu
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
| | - Zhuhui Chen
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
| | - Hui Jiang
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
| | - Yue Xiong
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
| | - Dong Liu
- Anhui Engineering Laboratory for Conservation and Sustainable Utilization of Traditional Chinese Medicine Resources, School of Biological and Pharmaceutical Engineering, West Anhui University, Liu'an, China
| | - Deli Xiao
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, China
- Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, China
- Key Laboratory of Biomedical Functional Materials, China Pharmaceutical University, Nanjing, China
| |
Collapse
|
5
|
Aalapati KK, Singh A, Patnaik RS. Method Development and Validation of a Novel UHPLC Coupled with
MS/MS System for the Estimation of Brivaracetam in Human (K2EDTA)
Plasma Samples and its Application to Pharmacokinetic Study. CURR PHARM ANAL 2022. [DOI: 10.2174/1573412917666210503113118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Brivaracetam is a novel antiepileptic drug clinically approved for the treatment
of partial onset seizures in adults and adolescents. It has some abuse potential and assigns to
Schedule V category under the Controlled Substance Act by the Drug Enforcement Administration.
It is essential to develop a faster, simple, and highly sensitive method for the quantification of
Brivaracetam in human plasma by employing simple liquid-liquid extraction.
Objective:
The objective of this study is to develop and validate a novel UHPLC-MS/MS method
for the estimation of brivaracetam in human plasma samples and application to pharmacokinetic
study.
Methods:
An ultra-high-pressure liquid chromatography-tandem mass spectrometry method was
developed and validated according to current regulatory guidelines for bioanalytical methods. Sample
processing (50 μL) involved only a simple liquid-liquid extraction by ethyl acetate as extraction
solvent. Brivaracetam-d7 was used as an internal standard. The chromatographic analysis was
performed by a Unisol C18 (4.6 X 100 mm, 5μm) column using 0.1% formic acid in water/acetonitrile
(20/80 V/V) as an isocratic mobile phase, at a flow rate of 1.0 mL/min with a run time of 2.2
min. Brivaracetam and its internal standard Brivaracetam D7 were detected and quantified in positive
ion mode using multiple reaction monitoring transitions at m/z 213.100→168.100 and m/z
220.000→175.100, respectively. The developed method was applied to assess pharmacokinetic parameters
like Cmax, Tmax, t1/2 and AUC for Brivaracetam in healthy, male, and adult humans.
Results:
The method was validated over a concentration range of 20.000 ng/mL to 4000. 000
ng/mL. Both intra- and inter-assay precision and accuracy were <15% for all quality control samples.
No matrix effect was observed. Pharmacokinetic results showed that test formulation is bioequivalent
with reference formulation.
Conclusion:
The present assay is faster, highly sensitive and simpler than previously published analytical
reports for brivaracetam in human plasma samples and is suitable for pharmacokinetic evaluation
of any marketed formulation.
Collapse
Affiliation(s)
- Kiran Kumar Aalapati
- Department of Clinical Research, School of Biological and Biomedical Sciences, Galgotias University, Greater Noida,
Uttar Pradesh, India
| | - Amit Singh
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University,
Greater Noida, Uttar Pradesh, India
| | - Ranjana S. Patnaik
- School of Biological and Biomedical Sciences, Galgotias University, Greater
Noida, Uttar Pradesh, India
| |
Collapse
|
6
|
da Silva JD, Cabral LM, de Sousa VP. Stability Indicating Methods for Determination of Third Generation Antiepileptic Drugs and Their Related Substances. Crit Rev Anal Chem 2021; 52:1524-1536. [PMID: 33678075 DOI: 10.1080/10408347.2021.1890544] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The third generation of antiepileptic drugs that have been approved by international regulatory agencies between 2007 and 2018 include rufinamide, stiripentol, eslicarbazepine acetate, lacosamide, perampanel, brivaracetam and everolimus. As part of demonstrating their safety profile, stability indicating methods are developed to monitor these drugs and their impurities. In this context, this review describe some characteristics, impurities and the stability indicating methods used for the determination of these drugs and the presence of their related substances. Through a search in official compendia and scientific articles, fifty-six analytical methodologies were identified up to October 2020. The methodologies were developed using techniques of HPLC, UPLC, HPTLC, GC and UV/Vis spectrophotometry. A majority of the methods (∼70%) employed HPLC-UV. A number of these antiepileptic drugs were found to have had a small number of studies related to their stability and for the detection of impurities. The presentation of the current level of research on third generation antiepileptic drugs highlights the need for new stability and safety studies that are necessary to develop new pharmaceutical products containing these drugs.
Collapse
Affiliation(s)
- Jéssica Domingos da Silva
- Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Lucio Mendes Cabral
- Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Valéria Pereira de Sousa
- Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| |
Collapse
|